Tests an inhaler against a placebo inhaler in people with COPD and hyperinflation
Compares a combination inhaler with a placebo inhaler for heart and lung function in COPD.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Key facts
- Where
- Ahrensburg, Berlin, Frankfurt am Main, and Hanover, GermanySee the 4 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07073950, who can take part
Where in Germany
- Velocity Clinical Research Germany GmbHAhrensburg, GermanyTaking people
- Parexel International GmbHBerlin, GermanyTaking people
- IKF Pneumologie GmbH & Co. KGFrankfurt am Main, GermanyTaking people
- The Fraunhofer Institute For Toxicology And Experimental Medicine ITEMHanover, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07073950EU 2025-521987-37-00
- Record updated
- 18 September 2026
- Original description
The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.Read full original descriptionShow less
A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation
The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.
Inclusion: Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking; A diagnosis of COPD confirmed by a post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) < 0.7; At Visit 1: A pre-bronchodilator FEV1 < 80%; At Visit 1: Peripheral blood eosinophil count < 300 cells/cubic millimeter (mm³), with no recorded history of eosinophil count > 300 cells/mm³ in the past 12 months; At Visit 1: Modified Medical Research Council (mMRC) ≥ 1; At Visit 2: A pre-bronchodilator functional residual capacity (FRC) of > 135% of predicted normal FRC; At Visit 2: A post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted normal value; Participants must be on mono-, dual-, or triple-inhaled maintenance COPD treatment; Female participants must either be not of childbearing potential or using a form of highly effective birth control; All women of child bearing potential must have a negative pregnancy test at the Visit 1.
Exclusion: Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening/run-in period; Participants with lung lobectomy, lung volume reduction (during the study and within 3 months of Visit 1), or lung transplantation; A current diagnosis of asthma, asthma-COPD overlap, or any other chronic respiratory disease other than COPD, such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension; History of a COPD exacerbation that required hospitalisation, or 2 or more COPD exacerbations that required systemic corticosteroids; History of myocardial infarction or acute coronary syndrome; History or current clinically significant atrial or ventricular arrhythmia to be confirmed by electrocardiogram (ECG); Participants with a cardiac implantable electronic device, including pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy; Participants with ECG QTcF interval at Visit 1 > 460 milliseconds (ms) for males and > 480 ms for females.